Tevogen Bio Holdings Inc.

What they do

Tevogen operates through three initiatives described in its 10-Q: Tevogen Bio, which develops off-the-shelf, precision allogeneic CD8+ cytotoxic T lymphocyte therapies using its ExacTcell platform; Tevogen.AI, which applies machine learning tools PredicTcell and AdapTcell to immunology and drug development; and Tevogen Healthcare Services, an early-stage healthcare services initiative. The lead product candidate, TVGN 489, is initially being developed for COVID-19 in immunocompromised and high-risk elderly patients, with potential Long COVID applications. The company has completed a Phase 1 proof-of-concept trial of TVGN 489 in ambulatory, high-risk adult COVID-19 patients. No product is described as approved or marketed in the filings.

Revenue drivers

• Tevogen Bio (T cell therapeutics) — The company's main initiative is development-stage; the filings describe no approved product or product revenue, only a completed Phase 1 trial of TVGN 489. No revenue contribution is disclosed.
• Tevogen.AI — Described as an initiative leveraging artificial intelligence and advanced data analytics for precision medicine, with tools PredicTcell and AdapTcell. No revenue or size is disclosed in the excerpts.
• Tevogen Healthcare Services — Described as an emerging, early-stage initiative intended to support longer-term efforts to improve healthcare affordability, accessibility and efficiency. No revenue or size is disclosed.

Recent performance

Tevogen has no reported product revenue in the excerpts; annual net losses were $60.5M in 2023, $13.7M in 2024 and $26.3M in 2025, with diluted EPS of -$2.44, -$3.50 and -$8.08, respectively. Operating cash flow was negative $8.2M in 2023, negative $12.0M in 2024 and negative $12.3M in 2025. As of June 30, 2026, the balance sheet showed total assets of $4.7M, total liabilities of $13.6M, shareholder equity of negative $8.9M, and cash and equivalents of $1.1M. The company effected a 1-for-50 reverse split of its common stock on March 6, 2026, and had 4,187,505 shares outstanding as of April 28, 2026.

Strategy

The company states it is focused on developing off-the-shelf, precision T cell therapies intended to be infused in patients other than the original donor, using its ExacTcell processes to develop, enrich and expand single HLA-restricted CTL therapies. It intends TVGN 489 to address COVID-19 in immunocompromised and high-risk elderly patients, with potential treatment and prevention applications for Long COVID. It is also building Tevogen.AI for target detection, clinical trial design and HLA specificity mapping, and has established the early-stage Tevogen Healthcare Services initiative. The company says it continues to build its intellectual property portfolio through patents, trademarks and trade secrets, including U.S. patents and applications covering product candidates, methods of use and methods of preparation.

Risks

• Going-concern and liquidity — As of June 30, 2026, the company reported $1.1M of cash and equivalents, total liabilities of $13.6M and negative shareholder equity of $8.9M, indicating limited resources relative to obligations.
• No approved product or revenue — The filings describe a completed Phase 1 proof-of-concept trial for TVGN 489 but no approved or marketed product and no product revenue.
• Nasdaq listing-rule failure — An 8-K filed April 22, 2026 reported a delisting notice or listing-rule failure, and a 1-for-50 reverse stock split was effected March 6, 2026.
• Clinical and regulatory uncertainty — TVGN 489 remains a development-stage candidate, and the company's ability to commercialize depends on obtaining and maintaining patents and other protection and on future clinical and regulatory outcomes.

Outlook

The excerpts do not include explicit forward guidance. The most recent 10-Q describes TVGN 489 as initially targeting COVID-19 in immunocompromised and high-risk elderly patients with potential Long COVID applications, and describes Tevogen.AI and Tevogen Healthcare Services as continuing initiatives, with the latter still at an early stage. Recent 8-K filings between January and September 2026 covered officer and director changes, charter amendments, shareholder votes, a delisting notice, and Regulation FD disclosures, but the excerpts do not state specific financial or operational targets.